Literature DB >> 3170583

Biochemical properties of SV40 large tumor antigen as a glycosylated protein.

D L Jarvis1, J S Butel.   

Abstract

The large tumor antigen (T-ag) of SV40 is a virus-encoded polypeptide that provides multiple biological activities required for virus replication and cellular transformation. T-ag is an exceptional model for the study of protein processing, because it displays a variety of chemical modifications and an unusual dual subcellular distribution. The cellular mechanisms responsible for the synthesis and processing of T-ag are unknown. With respect to glycosylation, this has been related to a lack of knowledge of the biochemical properties of T-ag as a glycoprotein. Several such properties are characterized here. We found that T-ag is glycosylated at multiple sites on the polypeptide chain. The oligosaccharides appear to belong to a single size class, molecular weight approximately 400, and the linkage between the polypeptide and the carbohydrate side chain is sensitive to beta-elimination under mild alkaline conditions. At least one glycosylation site was localized to the region between amino acids 1 and 272 (probably between residues 83 and 272), and at least one additional site was localized to a separate region, between amino acids 523 and 708. The results of cycloheximide experiments suggested that glycosylation of T-ag is a cotranslational event, and both the nuclear and the membrane-associated forms of T-ag appeared to be glycosylated. The results of these studies verify previous conclusions that the cellular secretory pathway is not involved in the glycosylation of T-ag; instead, a cytoplasmic mechanism might be involved.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170583

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  1 in total

1.  Initial characterization of the membrane-associated form of ICP4 of herpes simplex virus type 1.

Authors:  L Xia; R J Courtney
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.